This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • /
  • A Randomized, Double-blind, Placebo-controlled Pha...
Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma

Read time: 2 mins
Last updated:15th May 2013
Identifier: NCT01776840
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
Category Value
Date last updated at source 2017-06-01
Study type(s) Interventional
Expected enrolment 524
Study start date 2013-05-16
Estimated primary completion date 2021-10-10

View full details